• A glycomic workflow for LC-MS/MS analysis of urine glycosaminoglycan biomarkers in mucopolysaccharidoses
• A novel approach in diagnosing multiple dentigerous cysts using CBCT illustration indicative of Mucopolysaccharidosis VI - a case report
• Abnormal dental follicle cells: A crucial determinant in tooth eruption disorders (Review)
• Addressing the need for patient-friendly medical communications: adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA
• Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
• Airway management in mucopolysaccharidosis: a retrospective case series review
• Airway management of a child with mucopolysaccharidosis undergoing cervical spine surgery: A case report
• Atlantoaxial instability in a case of Maroteaux-Lamy syndrome
• Awake airway endoscopy in mucopolysaccharidosis: a case report
• Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI-LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT)
• Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study
• Case Report: Reinterpretation and Reclassification of <em>ARSB</em>:p.Arg159Cys Variant Identified in an Emirati Patient With Hearing Loss Caused by a Pathogenic Variant in the <em>CDH23</em> Gene
• Causes of death in mucopolysaccharidoses
• Changes in Corneal Clouding Over Time in Patients With Mucopolysaccharidosis
• Clinical and event-based outcomes of patients with mucopolysaccharidosis VI receiving enzyme replacement therapy in Turkey: a case series
• Clinical, Endocrine and Genetic spectrums of Mucopolysaccharidoses type VI in Duhok city, Kurdistan Region, Iraq
• Comparison of growth dynamics in different types of MPS: an attempt to explain the causes
• Compound heterozygous missense mutations in a Chinese mucopolysaccharidosis type VI patient: a case report
• Consensus on diagnosis and treatment of mucopolysaccharidosis A
• Consensus on diagnosis and treatment of mucopolysaccharidosis ⅣA
• Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia
• COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience
• Decreased Levels of Chaperones in Mucopolysaccharidoses and Their Elevation as a Putative Auxiliary Therapeutic Approach
• Deep intronic variant in the ARSB gene as the genetic cause for Maroteaux-Lamy syndrome (MPS VI)
• Defect-free graphene enhances enzyme delivery to fibroblasts derived from patients with lysosomal storage disorders
• Delayed Onset Post-Operative Neurologic Deficit in a Patient With Mucopolysaccharidosis type VI: A Case Report
• Difficulties Associated with Enzyme Replacement Therapy for Mucopolysaccharidoses
• Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries
• Double valve replacement in a patient with Maroteaux - Lamy syndrome as an ultimate team challenge
• Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI
• Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis
• Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI
• Epidemiology and Genetics of Mucopolysaccharidosis Type VI in Russia
• Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities
• Evaluation of bone health in patients with mucopolysaccharidosis
• Evaluation of cardiac findings in mucopolysaccharidosis
• Evaluation of sleep-disordered breathing and its relationship with respiratory parameters in children with mucopolysaccharidosis Type IVA and VI
• Extensive and Persistent Dermal Melanocytosis in a Male Carrier of Mucopolysaccharidosis Type IIIC (Sanfilippo Syndrome): A Case Report
• Fifteen years of enzyme replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a case report
• Flaxseed extract reduces tissue accumulation and enhances urinary excretion of chondroitin sulphate in the rat: a possible new path in substrate reduction therapy for mucopolysaccharidosis
• Functional results after carpal tunnel release in mucopolysaccharidosis
• Generation of a novel disease model mouse for mucopolysaccharidosis type VI via c. 252T&gt;C human <em>ARSB</em> mutation knock-in
• Generation of a novel disease model mouse for mucopolysaccharidosis type VI via c. 252T>C human ARSB mutation knock-in
• Generation of induced pluripotent stem cell line (RCMGi012-A) from fibroblasts of patient with mucopolysaccharidosis type VI
• Glycosaminoglycan-induced proinflammatory cytokine levels as disease marker in mucopolysaccharidosis
• Hearing Loss in Mucopolysaccharidosis
• Hyo-Mental Angle and Distance: An Important Adjunct in Airway Assessment of Adult Mucopolysaccharidosis
• Impaired ion homeostasis as a possible associate factor in mucopolysaccharidosis pathogenesis: transcriptomic, cellular and animal studies
• Increased Cerebral Serum Amyloid A2 and Parameters of Oxidation in Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase)-Null Mice
• Increased Cerebral Serum Amyloid A2 and Parameters of Oxidation in Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase)-Null Mice
• Increased ocular wall thickness and decreased globe volume in children with mucopolysaccharidosis type VI
• Liver-Directed Adeno-Associated Virus-Mediated Gene Therapy for Mucopolysaccharidosis Type VI
• Long-term outcome of hematopoietic stem cell transplantation in two children with Mucopolysaccharidosis
• Mandibular condyle morphology among patients with mucopolysaccharidosis: An observational study of panoramic radiographs
• Modeling cartilage pathology in mucopolysaccharidosis VI using iPSCs reveals early dysregulation of chondrogenic and metabolic gene expression
• Molecular analysis and novel variation identification of Chinese pedigrees with mucopolysaccharidosis using targeted next-generation sequencing
• Molecular characterization of a large cohort of mucopolysaccharidosis patients: Iran Mucopolysaccharidosis RE-diagnosis study (IMPRESsion)
• MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment
• Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients
• Mucopolysaccharidosis Type VI with Recurrent Chest Infection
• Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
• Mucopolysaccharidosis VI in a European Shorthair cat: Neurological presentation, computed tomography findings and genetic investigation
• Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and an Update of the "Gold Standard" Criteria Required to Make a Confirmatory Diagnosis
• Neutrophils and monocytes with increased azurophilic granules resembling toxic changes in mucopolysaccharidosis type VI
• New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases
• Novel chorioretinal findings in two siblings with mucopolysaccharidosis type VI
• Objectively measuring anterior segment alterations in the eyes of mucopolysaccharidoses: Its utility in early diagnosis of glaucoma
• Oral manifestations of Maroteaux-Lamy syndrome (Mucopolysaccharidosis VI)
• Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil
• Ovarian Mucinous Carcinoma in a Pediatric Patient With Maroteaux-Lamy Syndrome
• Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10-year prospective study
• Phenotypic expansion of ARSK-related mucopolysaccharidosis
• Preoperative cardiac POCUS for urgent surgery in a patient with Maroteaux-Lamy syndrome
• Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases
• Psychobehavioral factors and family functioning in mucopolysaccharidosis: preliminary studies
• Quantification of Glycosaminoglycans in Urine by Isotope-Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry
• Radiographic Findings of Mucopolysaccharidosis and Comparison with Bone Mineral Density: A Study from Southeastern Turkey
• Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey
• Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
• Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
• Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases
• Safety outcomes and patients' preferences for home-based intravenous enzyme replacement therapy (ERT) in pompe disease and mucopolysaccharidosis type I (MPS I) disorder: COVID-19 and beyond
• Skeletal phenotype amelioration in mucopolysaccharidosis VI requires intervention at the earliest stages of postnatal development
• Specific GAG ratios in the diagnosis of mucopolysaccharidoses
• Spinal cord compression in patients with mucopolysaccharidosis
• Staged Bilateral Total Hip Arthroplasty in a 17-Year-Old With Type VI Mucopolysaccharidosis
• Successful combined umbilical cord blood and bone marrow transplantation from an HLA-matched sibling for MPS VI: a case report
• Tandem mass spectrometric assay of N-acetylglucosamine-6-sulfatase for multiplex analysis of mucopolysaccharidosis-IIID in dried blood spots
• The clinical and genotypic-phenotypic findings of mucopolysaccharidosis VI patients: an Iraqi single-study descriptive study
• The experiences and support needs of siblings of people with mucopolysaccharidosis
• The first mucopolysaccharidosis type VII in a Taiwanese girl: A case report and review of the literature
• The impact of Chinese COVID-19 pandemic on the incidence of peripheral facial nerve paralysis after optimizing policies
• The intermediate outcomes of delegation of obligations of medicinal support of patients with rare diseases to the Federal level in 2019-2020
• The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Different Donors in Recipients With Mucopolysaccharidosis
• Transversus thoracis muscle plane blocks for a patient with Maroteaux-Lamy syndrome undergoing mitral valve replacement
• Understanding the challenges, unmet needs, and expectations of mucopolysaccharidoses I, II and VI patients and their caregivers in France: a survey study
• Untargeted LC-HRMS metabolomics reveals candidate biomarkers for mucopolysaccharidoses
• Updated Confirmatory Diagnosis for Mucopolysaccharidoses in Taiwanese Infants and the Application of Gene Variants
• Vertebral Tongue-Like Deformity in Mucopolysaccharidosis VI
• Visual impairment in mucopolysaccharidosis VI